Novo Nordisk A/S saw its shares fall 2.3% on August 4, despite the company increasing its full-year sales and operating profit forecast. The Danish pharmaceutical giant now expects sales growth of 18%-27% at constant exchange rates, up from the previous 18%-26%, and operating profit growth of 20%-29%, an increase from the prior 19%-27%. This upward revision was driven by robust demand for its GLP-1 obesity and diabetes drugs, particularly Wegovy, which continues to gain market share.
The market's muted reaction and subsequent stock drop were primarily attributed to the recent failure of Novo Nordisk's cardiovascular drug candidate, Ziltivekimab, in its Phase 3 ZEUS trial. This setback, announced on July 31, significantly overshadowed the positive earnings guidance. The ZEUS trial failed to demonstrate a reduction in major adverse cardiovascular events, despite successfully lowering inflammatory biomarkers.
Analysts noted that while the earnings update was positive on its own, the Ziltivekimab trial failure had already reset investor expectations and shifted focus away from the strong performance of the GLP-1 franchise. The company's stock had previously dropped 13% in Copenhagen following the Ziltivekimab news, touching levels not seen since July 2021. The market seems to be more concerned with pipeline diversification and future growth avenues beyond its current blockbusters, which the Ziltivekimab failure has complicated.
The company confirmed that the ZEUS outcome would not impact its 2026 adjusted operating profit outlook, though it would result in a non-cash impairment charge in the third quarter of 2026. This indicates that while the immediate financial impact might be manageable, the long-term strategic implications regarding pipeline strength and growth outside of GLP-1s are weighing heavily on investor sentiment. The update also comes ahead of Novo Nordisk's first-half results, which are anticipated on August 5, with options markets predicting an unusually high level of volatility.
